$2.52 Billion is the total value of BB BIOTECH AG's 29 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 3.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Celgene Corp. | $361,255,000 | -16.4% | 3,609,298 | 0.0% | 14.36% | +17.9% | |
| INCY | Buy | Incyte Corp. | $278,314,000 | -31.6% | 3,840,406 | +2.4% | 11.06% | -3.5% |
| IONS | Buy | Ionis Pharmaceuticals Inc. | $274,583,000 | -32.1% | 6,779,838 | +3.8% | 10.91% | -4.2% |
| GILD | Gilead Sciences Inc. | $254,874,000 | -9.2% | 2,774,596 | 0.0% | 10.13% | +28.1% | |
| ALXN | Alexion Pharmaceuticals Inc. | $144,013,000 | -27.0% | 1,034,428 | 0.0% | 5.72% | +3.0% | |
| RDUS | Buy | Radius Health Inc. | $137,091,000 | -47.9% | 4,360,399 | +2.1% | 5.45% | -26.4% |
| NBIX | Neurocrine Biosciences Inc. | $123,457,000 | -30.1% | 3,121,552 | 0.0% | 4.91% | -1.3% | |
| MDVN | Medivation Inc. | $118,680,000 | -4.9% | 2,581,112 | 0.0% | 4.72% | +34.2% | |
| VRTX | Vertex Pharmaceuticals Inc. | $108,539,000 | -36.8% | 1,365,445 | 0.0% | 4.31% | -10.9% | |
| AGIO | Agios Pharmaceuticals Inc. | $87,693,000 | -37.5% | 2,159,921 | 0.0% | 3.48% | -11.8% | |
| ALNY | Buy | Alnylam Pharmaceuticals Inc. | $74,780,000 | -29.9% | 1,191,338 | +5.2% | 2.97% | -1.0% |
| REGN | Regeneron Pharmaceuticals Inc. | $73,890,000 | -33.6% | 205,000 | 0.0% | 2.94% | -6.3% | |
| HALO | Buy | Halozyme Therapeutics Inc. | $69,887,000 | -42.6% | 7,379,832 | +5.0% | 2.78% | -19.1% |
| TSRO | Tesaro Inc. | $54,138,000 | -15.8% | 1,229,582 | 0.0% | 2.15% | +18.8% | |
| JUNO | Juno Therapeutics, Inc. | $49,707,000 | -13.4% | 1,305,000 | 0.0% | 1.98% | +22.3% | |
| NVAX | Novavax Inc. | $42,983,000 | -38.5% | 8,330,000 | 0.0% | 1.71% | -13.3% | |
| ALDR | Alder Biopharmaceuticals Inc. | $36,984,000 | -25.9% | 1,510,150 | 0.0% | 1.47% | +4.6% | |
| CEMP | Buy | Cempra Inc. | $35,774,000 | -42.3% | 2,041,900 | +2.5% | 1.42% | -18.6% |
| KITE | Kite Pharma, Inc. | $34,433,000 | -25.5% | 750,000 | 0.0% | 1.37% | +5.1% | |
| ICPT | Intercept Pharmaceuticals Inc. | $32,852,000 | -14.0% | 255,719 | 0.0% | 1.31% | +21.4% | |
| SAGE | Buy | Sage Therapeutics, Inc. | $26,727,000 | -35.3% | 833,663 | +17.6% | 1.06% | -8.8% |
| ESPR | Buy | Esperion Therapeutics, Inc. | $17,054,000 | -15.7% | 1,008,542 | +11.0% | 0.68% | +18.9% |
| PRTA | Buy | Prothena Corp. PLC | $14,406,000 | -33.9% | 350,000 | +9.4% | 0.57% | -6.7% |
| INFI | Infinity Pharmaceuticals Inc. | $14,233,000 | -32.9% | 2,700,737 | 0.0% | 0.57% | -5.2% | |
| PBYI | Puma Biotechnology Inc. | $12,688,000 | -62.5% | 431,991 | 0.0% | 0.50% | -47.2% | |
| CLVS | Clovis Oncology Inc. | $10,141,000 | -45.1% | 528,188 | 0.0% | 0.40% | -22.6% | |
| ACHN | Achillion Pharmaceuticals Inc. | $9,877,000 | -28.4% | 1,279,340 | 0.0% | 0.39% | +1.0% | |
| CDTX | Buy | Cidara Therapeutics, Inc. | $9,485,000 | +18.4% | 746,824 | +60.0% | 0.38% | +66.8% |
| PTCT | Sell | PTC Therapeutics Inc. | $7,618,000 | -82.0% | 1,182,912 | -9.2% | 0.30% | -74.5% |
| TTPH | Exit | Tetraphase Pharmaceuticals Inc. | $0 | – | -366,203 | -100.0% | -0.10% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N.V. #1
- Biotech Invest N.V. #2
- Biotech Target N.V. #3
- Biotech Growth N.V. #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.